



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 13.11.2025

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
205(A), 2nd floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West), Mumbai – 400070.  
Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 13<sup>th</sup> November, 2025 -  
Reg.

Ref: Disclosure under Regulation 30 & 33 SEBI (Listing Obligations and  
Disclosure Requirements) Regulations, 2015- Reg.

\*\*\*

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e., on Thursday, 13<sup>th</sup> November, 2025 had inter-alia transacted and approved the following items of business:

1. Approved the Un-audited Financial Results along with the Segment results for the quarter and half year ended 30<sup>th</sup> September, 2025
2. Approved the Statement of Assets and Liabilities as at 30<sup>th</sup> September, 2025.
3. Approved the Cash Flow Statement as at 30<sup>th</sup> September, 2025.
4. Approved the Related Party Transaction for change of corporate office with effect from 15-11-2025 and approved the draft Lease deed for shifting of corporate office in the same floor and in the same complex, which is owned by mother of the Executive Director, wife of the chairman of the company. The details of particulars of lease is placed as **Annexure A**.



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001, Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

5. Approved the change of Corporate Office of the Company from **402, 4<sup>th</sup> Floor, Raghava Ratna Towers, Chirag Ali Lane, Hyderabad 500001, Telangana, India** to **411, 4<sup>th</sup> Floor, Raghava Ratna Towers, Chirag Ali Lane, Hyderabad 500001, Telangana, India** with effect from 15.11.2025.

6. Approved the maintenance of books of accounts of the company at the new corporate office of the company situated at Office No. 411, 4<sup>th</sup> Floor, Raghava Ratna Towers, Chirag Ali Lane, Hyderabad 500001, Telangana India with effect from 15.11.2025.

7. Approved the reconstitution of the following Committee's:

**Audit Committee:**

1. Dr. Govindarajula Venkata Narasimha Rao, 2. Mr. Tunuguntla Adinarayana, 3. Mr. Mohanrao Gurram, 4. Mrs. Shilpa Bung

**Nomination and remuneration Committee:**

1. Dr. Govindarajula Venkata Narasimha Rao, 2. Mr. China Sai Babu Puppala, 3. Ms. Sridevi Madati, 4. Mrs. Shilpa Bung

**Stakeholders Relationship Committee:**

1. Dr. Govindarajula Venkata Narasimha Rao, 2. Mr. Tunuguntla Adinarayana, 3. Mr. Mohanrao Gurram, 4. Mrs. Shilpa Bung

All the above committee(s) have been reconstituted on 13<sup>th</sup> November, 2025.

We herewith enclose the following:

A. Un-Audited Financial Results, Segment Results, the Statement of Assets and Liabilities and Cash Flow statement as at 30<sup>th</sup> September, 2025.

B. Limited Review Report of the Statutory Auditors for the quarter and half year ended 30<sup>th</sup> September, 2025.

C. Undertaking for Non-Applicability of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

D. Undertaking for Non Applicability of Regulations 51, 52 and 54 of SEBI (LODR), Regulations, 2015.



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

We wish to inform that the company has not issued any Non-Convertible Debt Securities, Non-Convertible Redeemable Preference Shares (NCRPS) and Commercial Papers or any other instruments and as such the SEBI circular no. SEBI/HO/DDHS/DDHS/CIR/P/2020/231 dated November 13, 2020 is not applicable to the company.

Kindly take the above on your records.

Thanking you,

Yours faithfully,  
For Sigachi Laboratories Limited

(S. Lekha Sai)  
Company Secretary

The meeting Commenced at 4 00 PM  
The Meeting Concluded at 6 00 PM



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

## Annexure A

S No.	Particulars	Remarks
1.	Type, material terms and particulars of the proposed transaction	Type Taking on Lease Material terms and Particulars. Taking on lease a premises which is semi furnished for shifting the corporate office of the company from 402, 4 <sup>th</sup> Floor, Raghava Ratna Towers, Chirag Ali Lane, Hyderabad 500001, Telangana India to 411, 4 <sup>th</sup> Floor, Raghava Ratna Towers, Chirag Ali Lane, Hyderabad 500001 Telangana India
2	Name of the related party and its relationship with the listed entity or its subsidiary, including nature of its concern or interest (financial or otherwise).	Mrs T. Bhagya Lakshmi, Mother of Executive Director and wife of the chairman of the company and one of the promoter of the company Nature of its concern or interest The proposed premises is owned by above related party
3	Tenure of the proposed transaction (particular tenure shall be specified).	Lease period - 5 years with effect from 15.11.2025 Lease rental deposit- Rs 84,000/- (interest free refundable)
4	Value of the proposed transaction.	Rs 21,000/- per month plus applicable GST /reverse charge and 5% increase every year on the lease rental.
5.	The percentage of the listed entity's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction (and for a RPT involving a subsidiary, such percentage calculated on the basis of the subsidiary's annual turnover on a standalone basis shall be additionally provided)	0.81% of the listed entity's annual turnover vis-à-vis one year lease rental.
6.	Transaction relates to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary.	Not Applicable
7.	Justification as to why the RPT is in the interest of the listed entity.	The new corporate office is at the same complex and same floor wherein the present corporate office is situated for about 30 years and the proposed office is semi furnished and convenient which is ready for occupation and the lease rental transaction is made at arms length basis as per the prevailing rates in the said complex
8.	A copy of the valuation or other external party report, if any such report has been relied upon.	Not Applicable
9.	Percentage of the counter-party's annual consolidated turnover that is represented by the value of the proposed RPT on a voluntary basis	Not Applicable
10.	Any other information that may be relevant	--

SIGACHI LABORATORIES LIMITED

Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, Sanga Reddy District, Telangana.

Tel No.: 040 - 23204230/23204273

Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in

CIN: L24230TG1994PLC018786

Statement of Unaudited Financial Results For the Quarter and Half Year Ended 30th September, 2025

(Rs. in Lakhs)

Sl.No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
1	Revenue from operations	30.40	127.76	120.12	158.16	260.36	312.23
2	Other income	14.60	21.71	32.63	36.31	34.23	65.95
3	Total Income (1+2)	45.00	149.47	152.75	194.47	294.59	378.18
4	Expenses						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	c) Impairment on Advances	-	-	-	-	-	75.00
	d) Fair Value Loss	-	-	-	-	-	68.77
	e) Employee benefits expense	11.94	10.51	10.33	22.45	20.42	42.90
	f) Finance costs	-	-	-	-	-	-
	g) Depreciation and amortization expense	5.78	5.78	6.27	11.56	11.57	23.17
	h) Other expenses	2.99	3.87	2.87	6.86	7.17	16.12
	Total Expenses	20.71	20.16	19.47	40.87	39.16	225.96
5	Profit/(Loss) before exceptional items and tax (3-4)	24.29	129.31	133.28	153.60	255.43	152.22
6	Exceptional Items	-	-	-	-	-	-
7	Profit/(Loss) before tax (5-6)	24.29	129.31	133.28	153.60	255.43	152.22
8	Tax expense						
	(a) Current tax	12.32	10.61	15.60	22.93	20.18	45.61
	(b) Deferred tax	(6.15)	9.70	7.29	3.55	(1.16)	(12.49)
	Total Tax Expense	6.17	20.31	22.89	26.48	19.02	33.12
9	Profit/(Loss) for the Period (7-8)	18.12	109.00	110.39	127.12	236.41	119.10
10	Other Comprehensive income (OCI)						
	(a) Items that will not be reclassified to profit or (loss)	(35.48)	206.16	215.00	170.68	489.61	247.67
	(b) Remeasurement gains/(losses) on defined benefit plans	-	-	-	-	-	0.57
	(c) Tax on Items that will not be reclassified to profit or (loss)	11.73	(29.48)	(22.36)	(17.75)	(50.92)	(35.52)
	(d) Items that will be reclassified to profit or (loss)	-	-	-	-	-	-
	(e) Items that may be reclassified subsequently to profit or (loss)	-	-	-	-	-	-
	Total other Comprehensive income for the period, net of tax	(23.75)	176.68	192.64	152.93	438.69	212.72
	Total Comprehensive income (9+10)	(5.63)	285.68	303.03	280.05	675.10	331.82
11	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	675.31	675.31	675.31	675.31	675.31	675.31
12	Other Equity	-	-	-	-	-	3,201.66
13	Earnings per equity share (of Rs.10/- each) (not annualized (in Rs.))						
	(1) Basic	0.27	1.61	1.63	1.88	3.50	1.76
	(2) Diluted	0.27	1.61	1.63	1.88	3.50	1.76

Segment wise Revenue, Results and Capital Employed for the Quarter and Half Year Ended 30th September, 2025

(Rs. in Lakhs)

Sl.No	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	39.00	25.00	34.50	64.00	57.50	140.50
	b) Investments	6.00	124.47	118.25	130.47	237.09	237.68
	Total	45.00	149.47	152.75	194.47	294.59	378.18
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net Sales/Income from Operations	45.00	149.47	152.75	194.47	294.59	378.18
2	Segment Results Profit/(Loss) before tax and finance costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	33.04	18.68	28.05	51.72	45.37	115.42
	b) Investments	6.00	124.47	118.25	130.47	237.09	168.91
	Total	39.04	143.15	146.30	182.19	282.46	284.33
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	14.75	13.84	13.02	28.59	27.03	132.11
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit/(loss) Before Tax	24.29	129.31	133.28	153.60	255.43	152.22
3	Capital Employed						
	(Segment Assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	733.22	699.51	781.47	733.22	781.47	791.09
	b) Investments	3,479.55	3,518.90	3,494.53	3,479.55	3,494.53	3,141.63
	Total	4,212.77	4,218.41	4,276.00	4,212.77	4,276.00	3,932.72

Notes :

- 1 The above unaudited Financial results as reviewed and recommended by the Audit Committee are considered and approved by the Board of Directors at their respective meetings held on 13th November, 2025.
- 2 These financial results of the company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 These Financial results have been subjected to limited review by the Statutory Auditors'.
- 4 These Financial Results are available on the Stock Exchange website (www.msei.in) and also on the company's website at (www.slllab.com).

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad  
Date : 13.11.2025

(T.R.Sekhar)  
Executive Director  
DIN:02943146

**SIGACHI LABORATORIES LIMITED**  
 Regd.Office: S.No: 530 & 534, Bonthapally - 502 313.  
 Gummadidala Mandal, Sanga Reddy District, Telangana.  
 Tel No.: 040 - 23204230 / 23204273  
 Website:www.slllab.com, Email:sigachilaboratories@yahoo.co.in  
 CIN:L24230TG1994PLC018786  
 Statement of Assets and Liabilities as at 30th September , 2025

(Rs.in lakhs)

Particulars	As at 30.09.2025	As at 31.03.2025
	(Unaudited)	(audited)
<b>A. ASSETS</b>		
1. Non Current Assets		
(a) Property, Plant and Equipment	500.87	310.27
(b) Financial Assets		
(i) Investments	3,292.99	2,967.63
(ii) Other Financial Assets	43.62	43.62
(c) Other Non Current Assets	215.50	396.25
<b>Total Non Current Assets</b>	<b>4,052.98</b>	<b>3,717.77</b>
2. Current Assets		
(a) Financial Assets		
(i) Investments	10.38	10.01
(ii) Trade Receivables	55.26	2.78
(iii) Cash and Cash Equivalents	88.08	186.48
(iv) Other Financial Assets	186.56	174.00
(b) Other Current Assets	8.37	0.29
<b>Total Current Assets</b>	<b>348.65</b>	<b>373.56</b>
<b>Total Assets</b>	<b>4,401.63</b>	<b>4,091.33</b>
<b>B. EQUITY AND LIABILITIES</b>		
1. Equity		
(a) Equity Share Capital	731.06	731.06
(b) Other Equity	3,481.71	3,201.66
<b>Total Equity</b>	<b>4,212.77</b>	<b>3,932.72</b>
2. Liabilities		
Non Current Liabilities		
(a) Financial Liabilities	-	-
(b) Provisions	8.03	8.03
(c) Deferred Tax Liabilities (net)	137.29	115.99
(d) Other Non Current Liabilities	35.00	25.00
<b>Total Non Current Liabilities</b>	<b>180.32</b>	<b>149.02</b>
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Trade Payables	-	-
(iii) Other Financial Liabilities	6.89	9.04
(b) Other Current Liabilities	-	-
(c) Provisions	1.65	0.55
<b>Total Current Liabilities</b>	<b>8.54</b>	<b>9.59</b>
<b>Total Equity and Liabilities</b>	<b>4,401.63</b>	<b>4,091.33</b>

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad  
Date : 13.11.2025

(T.R.Sekhar)  
Executive Director  
DIN:02943146

<b>Sigachi Laboratories Limited</b>		
<b>CASH FLOW STATEMENT FOR THE PERIOD/YEAR ENDED 30th September, 2025</b>		
(Rs.in lakhs)		
Particulars	For the Half Year Ended 30.09.2025 (Unaudited)	For the year ended 31.03.2025 (Audited)
Cash Flows from Operating Activities		
Profit/(loss) before tax	153.60	152.22
Adjustments for:		
Depreciation and amortization expense	11.56	23.17
(Profit)/loss on sale of Property, Plant and Equipment	-	-
Dividend Received	(21.38)	(50.75)
Provision for Gratuity & Leave Encashment	-	0.70
Provision for Impairment	-	75.00
Interest received	(44.61)	(68.49)
Fair Value Losses	-	68.77
Fair Value (Gains)/Losses	(64.48)	(118.21)
Operating profit before working capital changes	34.69	82.41
Movements in Working Capital		
(Increase)/Decrease in Trade Receivables	(52.48)	17.43
(Increase)/Decrease in Other Financial Assets	(12.56)	(3.02)
(Increase)/Decrease in Other Current Assets	(8.08)	(0.18)
(Increase)/Decrease in Other Non Current Assets	180.75	(0.75)
Increase/(Decrease) in Other Financial Liabilities	(2.15)	2.97
Increase/(Decrease) in Other Non Current Liabilities	10.00	-
Increase/(Decrease) in Provisions	1.10	(1.08)
(Increase)/Decrease in Other Non Current Financial Assets	-	-
Changes in Working Capital	116.58	15.37
Cash generated from operations	151.27	97.78
Direct Taxes Paid	22.93	45.61
Net Cash from operating activities (A)	128.34	52.17
Cash flows from Investing Activities		
(Purchase) of Property, Plant and Equipment	(202.16)	(11.84)
(Purchase) of Investments	(29.51)	(71.75)
Sale of Investments	0.02	40.64
Dividend Received	21.38	50.75
Interest Received	44.61	68.49
(Increase)/Decrease in other term deposits	(61.08)	13.49
Net Cash used in Investing Activities (B)	(226.74)	89.78
Cash flows from/(used in) Financing Activities		
Proceeds from Long term borrowings	-	-
Repayment/(Proceeds) of/from Short-term borrowings	-	-
Dividend paid	-	-
Net Cash used in Financing Activities (C)	-	-
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(98.40)	141.95
Cash and Cash Equivalents at the beginning of the year	186.48	44.53
Cash and Cash Equivalents at the ending of the year	88.08	186.48

for SIGACHI LABORATORIES LIMITED

Place : Hyderabad  
Date : 13.11.2025

(T.R.Sekhar)  
Executive Director  
DIN:02943146

**Independent Auditor's Review Report on the Quarter and half year ended 30<sup>th</sup> September, 2025  
Unaudited Financial Results of the Company pursuant to the Regulations 33 of the SEBI (Listing  
Obligations and Disclosure Requirements) Regulations, 2015, as amended**

To The Board of Directors of **SIGACHI LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited financial results of **SIGACHI LABORATORIES LIMITED** ('the Company') for the quarter and half year ended 30<sup>th</sup> September 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD 1/44/2019 "Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Our conclusion on the statement in respect of these matters is not modified with respect to the financial results and other financial information certified by the management.

**For M/s. NSVR & ASSOCIATES LLP**

Chartered accountants

FRN: 008801S/S200060



**Venkata Ratnam P**

Partner

Membership No: 230675

UDIN: 25230675 BMINLA 2743

Place: Hyderabad

Date : 13-11-2025



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 13.11.2025

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
205(A), 2nd floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West), Mumbai – 400070

Dear Sir,

Sub: Non-Applicability of Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Reg.

\*\*\*

Pursuant to the Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the company had made its public offer (Initial Public Offer IPO) nearly about 25 years back and the Company has fully utilized the proceeds of the IPO for the purpose for which the funds were raised. The company has not raised any fresh issue after Initial public issue - through public issue, rights issue, preferential issue, QIP, etc., Hence, the Statement of deviation(s) or variation(s) is not applicable to the Company

We request you to kindly take note of this information on your record and acknowledge.

Thanking you,

Yours faithfully,  
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)  
Company Secretary



# SIGACHI LABORATORIES LIMITED

Corporate Office : 402, Raghava Ratna Towers,  
Chirag Ali Lane, Hyderabad - 500 001. Telangana (INDIA)  
Ph. : 040-23204230, 23204273, E-mail: sigachilaboratories@yahoo.co.in  
GSTIN: 36AACCS8220M1Z4 CIN : L24230TG1994PLC018786

Date: 13 11 2025

Head Listing & Compliance  
Metropolitan Stock Exchange of India Limited  
205(A), 2nd floor, Piramal Agastya Corporate Park,  
Kamani Junction, LBS Road,  
Kurla (West) Mumbai – 400 070

Dear Sir,

Sub: Sigachi Laboratories Limited - Intimation of Non Applicability of Regulations  
51, 52 and 54 of SEBI (LODR), Regulations, 2015 for the Quarter ended 30.9.2025-  
Reg

...

With respect to above cited subject, we would like to inform your good office that the following regulations of the SEBI (LODR) Regulations, 2015, as amended, are not applicable to our company:

S No.	Particulars	Regulation	Applicability
1.	Price Sensitive Information/ disclosure of event/ Information	Reg 51(1) & 51 (2) SEBI (LODR) Regulations, 2015	Debt
2.	Submission of Financial Results	Reg. 52(1) SEBI (LODR) Regulations, 2015	Debt
3.	Submission of line items along with Financial Results	Reg. 52(4) & 52 (6) SEBI (LODR) Regulations, 2015	Debt
4.	Asset Cover	Reg 54(2) & 54 (3) SEBI (LODR) Regulations, 2015	Debt
5.	Utilization of issue proceeds/ material deviation in the use of proceeds	Reg 52(7) & 52(7A) SEBI (LODR) Regulations, 2015	Debt

We hereby certify that the Company has not issued any non-convertible securities or instruments of similar nature at any time during the quarter ended 30.9.2025 and therefore the disclosures required as per aforementioned regulations are not applicable to the company

We request you to take the above in your records.

Thanking you,

Yours Faithfully  
For Sigachi Laboratories Limited

(Lekha Sai Surapaneni)  
Company Secretary